T cells reactive with HLA-A*0201 peptides from the histone demethylase JARID1B are found in the circulation of breast cancer patients

International Journal of Cancer

Volumn 128, Issue 9, 2011, Pages 2114-2124

  Coleman, Julia A ^a   Correa, Isabel ^a   Cooper, Lucienne ^a   Bohnenkamp, Hermann R ^a,c   Poulsom, Richard ^b   Burchell, Joy M ^a   Taylor Papadimitriou, Joyce ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c MILTENYI BIOTEC GMBH   (Germany)

Author keywords

Breast cancer; CD8; PLU 1 JARID1B KDM5B; T cell response

Indexed keywords

EPITOPE; GAMMA INTERFERON; HISTONE DEMETHYLASE; HLA A ANTIGEN; POLYMER; PROTEIN JARID1B; RETINOBLASTOMA BINDING PROTEIN 2; UNCLASSIFIED DRUG;

ALGORITHM; ANTIGEN PRESENTING CELL; ARTICLE; BINDING AFFINITY; BINDING COMPETITION; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELL STRAIN MCF 7; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IC 50; IMMUNOGENICITY; IMMUNOREACTIVITY; IN VITRO STUDY; LYMPHOBLAST; MEMORY T LYMPHOCYTE; PHENOTYPE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; SEQUENCE HOMOLOGY; T LYMPHOCYTE ACTIVATION;

ADULT; ANTIGENS, NEOPLASM; BREAST NEOPLASMS; CD8-POSITIVE T-LYMPHOCYTES; CELL SEPARATION; EPITOPES, T-LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; HISTONE DEMETHYLASES; HLA-A ANTIGENS; HUMANS; IN SITU HYBRIDIZATION; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; LYMPHOCYTE ACTIVATION; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; NUCLEAR PROTEINS; PEPTIDES; REPRESSOR PROTEINS;

EID: 79952459833     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25792     Document Type: Article

References (37)

1. Lambeck A, Leffers N, Hoogeboom B, Sluiter W, Hamming I, Klip H, ten Hoor K, Esajas M, van Oven M, Drijfhout J-W, Platteel I, Offringa R, et al. P53-specific T cell responses in patients with malignant and benign ovarian tumors: Implications for p53 based immunotherapy. Int J Cancer 2007;121:606-14. (Pubitemid 46986494)
2. Mackensen A, Meidenbauer N, Vogl S, Laumer M, Berger J, Andreesen R. Phase I study of adoptive T-cell therapy using antigen-specific CD8+ T cells for the treatment of patients with metastatic melanoma. J Clin Oncol 2006;24:5060-9. (Pubitemid 46631410)
3. Svane I, Pedersen A, Johansen J, Johnsen H, Nielsen D, Kamby C, Ottesen S, Balslev E, Gaarsdal E, Nikolajsen K, Claesson M. Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers. Cancer Immunol Immunother 2007;56:1485-99. (Pubitemid 47024713)
4. Ramlau R, Quoix E, Rolski J, Pless M, Lena H, Levy E, Krzakowski M, Hess D, Tartour E, Chenard MP, Limacher JM, Bizouarne N, et al. A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III/IV Non-small cell lung cancer. J Thorac Oncol 2008;3:735-44.
5. Doehn C, Esser N, Pauels HG, Kiessig ST, Stelljes M, Grossmann A, Jocham D, Drevs J.Mode-of-action, efficacy, and safety of a homologousmulti-epitope vaccine in a murinemodel for adjuvant treatment of renal cell carcinoma. EurUrol 2008;56:123-131.
6. Herd KA, Harvey T, Khromykh AA, Tindle RW. Recombinant Kunjin virus replicon vaccines induce protective T-cell immunity against human papillomavirus 16 E7-expressing tumour. Virology 2004;319:237-48. (Pubitemid 38251265)
7. Barrett A, Madsen B, Copier J, Lu PJ, Cooper L, Scibetta AG, Burchell J, Taylor-Papadimitriou J. PLU-1 nuclear protein, which is upregulated in breast cancer, shows restricted expression in normal human adult tissues: a new cancer/testis antigen? Int J Cancer 2002;101:581-8.
8. Barrett A, Santangelo S, Tan K, Catchpole S, Roberts K, Spencer-Dene B, Hall D, Scibetta A, Burchell J, Verdin E, Freemont P, Taylor-Papadimitriou J. Breast cancer associated transcriptional repressor PLU-1/JARID1B interacts directly with histone deacetylases. Int J Cancer 2007;121:265-75. (Pubitemid 46917694)
9. Lu PJ, Sundquist K, Baeckstrom D, Poulsom R, Hanby A, Meier-Ewert S, Jones T, Mitchell M, Pitha-Rowe P, Freemont P, Taylor-Papadimitriou J. A novel gene (PLU-1) containing highly conserved putative DNA/chromatin binding motifs is specifically up-regulated in breast cancer. J Biol Chem 1999;274:15633-45.
10. Madsen B, Spencer-Dene B, Poulsom R, Hall D, Lu PJ, Scott K, Shaw AT, Burchell JM, Freemont P, Taylor-Papadimitriou J. Characterisation and developmental expression of mouse Plu-1, a homologue of a human nuclear protein (PLU-1) which is specifically up-regulated in breast cancer. Gene Expr Patterns 2002;2:275-82. (Pubitemid 36358186)
11. Madsen B, Tarsounas M, Burchell JM, Hall D, Poulsom R, Taylor-Papadimitriou J. PLU-1, a transcriptional repressor and putative testis-cancer antigen, has a specific expression and localisation pattern during meiosis. Chromosoma 2003;2:275-282.
12. Hayami S, Yoshimatsu M, Veerakumarasivam A, Unoki M, Iwai Y, Tsunoda T, Field HI, Kelly JD, Neal DE, Yamaue H, Ponder BA, Nakamura Y, et al. Overexpression of the JmjC histone demethylase KDM5B in human carcinogenesis: involvement in the proliferation of cancer cells through the E2F/RB pathway. Mol Cancer 2010;9:59.
13. Patsialou A, Wilsker D, Moran E. DNA-binding properties of ARID family proteins. Nucleic Acids Res 2005;33:66-80. (Pubitemid 40276929)
14. Yamane K, Tateishi K, Klose RJ, Fang J, Fabrizio LA, Erdjument-Bromage H, Taylor-Papadimitriou J, Tempst P, Zhang Y. PLU-1 is an H3K4 demethylase involved in transcriptional repression and breast cancer cell proliferation. Mol Cell 2007;25:801-12. (Pubitemid 46436533)
15. Dey BK, Stalker L, Schnerch A, Bhatia M, Taylor-Papidimitriou J, Wynder C. The Histone Demethylase KDM5b/JARID1b Plays a Role in Cell Fate Decisions by Blocking Terminal Differentiation. Mol Cell Biol 2008;28:5312-27.
16. Scibetta AG, Santangelo S, Coleman J, Hall D, Chaplin T, Copier J, Catchpole S, Burchell J, Taylor-Papadimitriou J. Functional analysis of the transcription repressor PLU-1/JARID1B. Mol Cell Biol 2007;27:7220-35. (Pubitemid 47549757)
17. Ehlken H, Schadendorf D, Eichmuller S. Humoral immune response against melanoma antigens induced by vaccination with cytokine gene-modified autologous tumor cells. Int J Cancer 2004;108:307-13. (Pubitemid 37541788)
18. Parker K, Bednarek M, Coligan J. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol 1994;152:163-75.
19. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 1999;50:213-9. (Pubitemid 30099526)
20. Graham RA, Burchell JM, Beverley P, Taylor-Papadimitriou J. Intramuscular immunisation with MUC1 cDNA can protect C57 mice challenged with MUC1-expressing syngeneic mouse tumour cells. Int J Cancer 1996;65:664-70. (Pubitemid 26092295)
21. Hewitt EW, Gupta SS, Lehner PJ. The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. EMBO J 2001;20:387-96. (Pubitemid 32126975)
22. Alexander J, Sidney J, Southwood S, Ruppert J, Oseroff C, Maewal A, Snoke K, Serra HM, Kubo RT, Sette A, Grey HM. Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides. Immunity 1994;1:751-61.
23. Wierecky J, Muller MR, Wirths S, Halder-Oehler E, Dorfel D, Schmidt SM, Hantschel M, Brugger W, Schroder S, Horger MS, Kanz L, Brossart P. Immunologic and Clinical Responses after Vaccinations with Peptide-Pulsed Dendritic Cells in Metastatic Renal Cancer Patients. Cancer Res 2006;66:5910-18. (Pubitemid 43927146)
24. Brossart P, Heinrich KS, Stuhler G, Behnke L, Reichardt VL, Stevanovic S, Muhm A, Rammensee H-G, Kanz L, Brugger W. Identification of HLA-A2-restricted T-cell epitopes derived from the MUC1 tumor antigen for broadly applicable vaccine therapies. Blood 1999;93:4309-17. (Pubitemid 29279274)
25. Abrams SI, Hodge JW, McLaughlin JP, Steinberg SM, Kantor JA, Schlom J. Adoptive immunotherapy as an in vivo model to explore antitumor mechanisms induced by a recombinant anticancer vaccine. J Immunother 1997;20:48-59. (Pubitemid 28011523)
26. Cohen CJ, Hoffmann N, Farago M, Hoogenboom HR, Eisenbach L, Reiter Y. Direct detection and quantitation of a distinct T-cell epitope derived from tumor-specific epithelial cell-associated mucin using human recombinant antibodies endowed with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Cancer Res 2002;62:5835-44. (Pubitemid 35204743)
27. Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W. Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96:3102-8.
28. Correa I, Plunkett T, Coleman J, Galani E, Windmill E, Burchell JM, Taylor-Papdimitriou J. Responses of human T cells to peptides flanking the tandem repeat and overlapping the signal sequence of MUC1. Int J Cancer 2005;115:760-8. (Pubitemid 40776700)
29. Feuerer M, Rocha M, Bai L, Umansky V, Solomayer EF, Bastert G, Diel IJ, Schirrmacher V. Enrichment of memory T cells and other profound immunological changes in the bone marrow from untreated breast cancer patients. Int J Cancer 2001;92:96-105. (Pubitemid 32187038)
30. Beverley PC. Functional analysis of human T cell subsets defined by CD45 isoform expression. Semin Immunol 1992;4:35-41.
31. Merkenschlager M, Beverley PC. Evidence for differential expression of CD45 isoforms by precursors for memory-dependent and independent cytotoxic responses: human CD8 memory CTLp selectively express CD45RO (UCHL1). Int Immunol 1989;1:450-9. (Pubitemid 19263705)
32. Lanzavecchia A, Sallusto F. Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005;17:326-32. (Pubitemid 40692670)
33. Sallusto F, Langenkamp A, Geginat J, Lanzavecchia A. Functional subsets of memory T cells identified by CCR7 expression. Curr Top Microbiol Immunol 2000;251:167-71.
34. Sallusto F, Lenig D, Forster R, Lipp M, Lanzavecchia A. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 1999;401:708-12.
35. Andersen MH, Reker S, Becker JC, Straten Pt. The melanoma inhibitor of apoptosis protein: a target for spontaneous cytotoxic T cell responses. J Invest Dermatol 2004;122:392-99. (Pubitemid 38281060)
36. Klebanoff CA, Gattinoni L, Torabi-Parizi P, Kerstann K, Cardones AR, Finkelstein SE, Palmer DC, Antony PA, Hwang ST, Rosenberg SA, Waldmann TA, Restifo NP. Central memory self/tumor-reactive CD8+ T cells confer superior antitumor immunity compared with effector memory T cells. Proc Natl Acad Sci USA 2005;102:9571-6. (Pubitemid 40981722)
37. Iwase S, Lan F, Bayliss P, de la Torre-Ubieta L, Huarte M, Qi HH, Whetstine JR, Bonni A, Roberts TM, Shi Y. The X-linked mental retardation gene SMCX/JARID1C defines a family of histone H3 lysine 4 demethylases. Cell 2007;128:1077-88. (Pubitemid 46437259)